Form 4: Madrigal Pharmaceuticals Director Richard S. Levy Receives Stock and Option Grants

Director Richard S. Levy of Madrigal Pharmaceuticals received a grant of restricted stock units and a stock option on June 25, 2024.

Summary

• Richard S. Levy, a director of Madrigal Pharmaceuticals, reported changes in beneficial ownership on June 27, 2024.
• On June 25, 2024, Levy acquired 714 shares of common stock through a grant of restricted stock units at a price of $0.00.
• These restricted stock units vest on June 25, 2025, contingent upon continued service with the issuer.
• Levy also acquired a stock option to purchase 1,105 shares of common stock at an exercise price of $280.04, which vests on June 25, 2025.
• Following these transactions, Levy directly owns 11,012 shares of common stock and holds options for 1,105 shares.
• The reporting was filed by Mardi Dier, as Attorney-in-Fact, on behalf of Richard S. Levy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices. The grants incentivize the director, aligning their interests with the company's performance.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with the long-term success of the company.
• The vesting conditions encourage continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with shareholder value.

Stakeholder Impact

• The equity grants aim to align the director's interests with those of the shareholders, potentially leading to better corporate governance and performance.

Key Dates